BioArctic continues to build its commercial organization
Stockholm, February 18, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the company’s lead drug candidate, lecanemab, in the Nordic region. During the spring 2022 several key roles will be added to the organization.Since 2005 BioArctic has a long-standing cooperation with the global pharmaceutical company Eisai regarding development and commercialisation of the drug candidate lecanemab (BAN2401) for the treatment of early Alzheimer’s disease. The development of lecanemab is driven by Eisai, which also